Loading…

The incretin system in healthy humans: The role of GIP and GLP-1

The incretin effect, the amplification of insulin secretion occurring when glucose is taken in orally as compared to infused intravenously, is one of the factors that help the body to tolerate carbohydrate/glucose ingestion. These include 1) amount and type of carbohydrates; 2) gastric emptying rate...

Full description

Saved in:
Bibliographic Details
Published in:Metabolism, clinical and experimental clinical and experimental, 2019-07, Vol.96, p.46-55
Main Author: Holst, Jens Juul
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c478t-e5d630697a936c00623a5b00cefb3a3339cae0d71cb0230aa0075dfeb1b053df3
cites cdi_FETCH-LOGICAL-c478t-e5d630697a936c00623a5b00cefb3a3339cae0d71cb0230aa0075dfeb1b053df3
container_end_page 55
container_issue
container_start_page 46
container_title Metabolism, clinical and experimental
container_volume 96
creator Holst, Jens Juul
description The incretin effect, the amplification of insulin secretion occurring when glucose is taken in orally as compared to infused intravenously, is one of the factors that help the body to tolerate carbohydrate/glucose ingestion. These include 1) amount and type of carbohydrates; 2) gastric emptying rate; 3) digestion and absorption of the carbohydrates; 4) secretion and effect of the incretin hormones; 5) disposition of absorbed nutrients/glucose. The incretin effect can also be viewed as the fraction of the ingested glucose load handled via gastrointestinal mechanisms (including the incretin effect); it is calculated by comparison of the amount of glucose required to copy, by intravenous infusion, the oral load. Typically, for 75 g of oral glucose, about 25 g are required. This means that the GastroIntestinal Glucose Disposal (GIGD) is 66%. Both the GIGD and the incretin effect depend on the amount of glucose ingested: for higher doses the GIGD may amount to 80%, which shows that this effect is a major contributor to glucose tolerance. The main mechanism behind it is stimulation of insulin secretion by a proportional secretion of the insulinotropic hormones GIP and GLP-1. Recently it has become possible to estimate their contributions in healthy humans using specific and potent receptor antagonists. Both hormones act to improve glucose tolerance (i.e. the antagonists impair tolerance) and their effects are additive. GIP seems to be quantitatively the most important, particularly regarding insulin secretion, whereas the action of GLP-1 is mainly displayed via inhibition of glucagon secretion. •The incretin effect refers to the amplification of insulin secretion after oral versus intravenous glucose•It is responsible for the disposal of most of ingested glucose and therefore essential for glucose tolerance•The incretin effect is mainly due to the actions of the gut hormones GIP and GLP-1•Antagonist studies revealed that GIP is most important for insulin secretion, GLP-1 for inhibition of glucagon secretion
doi_str_mv 10.1016/j.metabol.2019.04.014
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2216775245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0026049519300861</els_id><sourcerecordid>2216775245</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-e5d630697a936c00623a5b00cefb3a3339cae0d71cb0230aa0075dfeb1b053df3</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwCSAv2SSM7dhu2ACqoFSqRBdlbTnORE2VR7ETpP49qVrYshqNdO48DiG3DGIGTD1s4xo7m7VVzIGlMSQxsOSMjJkUPJoqgHMyBuAqgiSVI3IVwhYAtJ6qSzISDHiqNYzJ83qDtGycx65saNiHDuuhpxu0VbfZ001f2yY80gPm2wppW9D5YkVtk9P5chWxa3JR2CrgzalOyOfb63r2Hi0_5ovZyzJyiZ52EcpcCVCptqlQDkBxYWUG4LDIhBVCpM4i5Jq5DLgAa4dbZV5gxjKQIi_EhNwf5-58-9Vj6ExdBodVZRts-2A4Z0pryRM5oPKIOt-G4LEwO1_W1u8NA3OQZ7bmJM8c5BlIzCBvyN2dVvRZjflf6tfWADwdARwe_S7Rm-BKbBzmpUfXmbwt_1nxA-QpgIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216775245</pqid></control><display><type>article</type><title>The incretin system in healthy humans: The role of GIP and GLP-1</title><source>ScienceDirect Freedom Collection</source><creator>Holst, Jens Juul</creator><creatorcontrib>Holst, Jens Juul</creatorcontrib><description>The incretin effect, the amplification of insulin secretion occurring when glucose is taken in orally as compared to infused intravenously, is one of the factors that help the body to tolerate carbohydrate/glucose ingestion. These include 1) amount and type of carbohydrates; 2) gastric emptying rate; 3) digestion and absorption of the carbohydrates; 4) secretion and effect of the incretin hormones; 5) disposition of absorbed nutrients/glucose. The incretin effect can also be viewed as the fraction of the ingested glucose load handled via gastrointestinal mechanisms (including the incretin effect); it is calculated by comparison of the amount of glucose required to copy, by intravenous infusion, the oral load. Typically, for 75 g of oral glucose, about 25 g are required. This means that the GastroIntestinal Glucose Disposal (GIGD) is 66%. Both the GIGD and the incretin effect depend on the amount of glucose ingested: for higher doses the GIGD may amount to 80%, which shows that this effect is a major contributor to glucose tolerance. The main mechanism behind it is stimulation of insulin secretion by a proportional secretion of the insulinotropic hormones GIP and GLP-1. Recently it has become possible to estimate their contributions in healthy humans using specific and potent receptor antagonists. Both hormones act to improve glucose tolerance (i.e. the antagonists impair tolerance) and their effects are additive. GIP seems to be quantitatively the most important, particularly regarding insulin secretion, whereas the action of GLP-1 is mainly displayed via inhibition of glucagon secretion. •The incretin effect refers to the amplification of insulin secretion after oral versus intravenous glucose•It is responsible for the disposal of most of ingested glucose and therefore essential for glucose tolerance•The incretin effect is mainly due to the actions of the gut hormones GIP and GLP-1•Antagonist studies revealed that GIP is most important for insulin secretion, GLP-1 for inhibition of glucagon secretion</description><identifier>ISSN: 0026-0495</identifier><identifier>EISSN: 1532-8600</identifier><identifier>DOI: 10.1016/j.metabol.2019.04.014</identifier><identifier>PMID: 31029770</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cytokines - physiology ; Glucagon-Like Peptide 1 - physiology ; Health Status ; Humans ; Incretins - physiology ; Insulin - metabolism ; Signal Transduction - physiology</subject><ispartof>Metabolism, clinical and experimental, 2019-07, Vol.96, p.46-55</ispartof><rights>2019 The Author</rights><rights>Copyright © 2019 The Author. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-e5d630697a936c00623a5b00cefb3a3339cae0d71cb0230aa0075dfeb1b053df3</citedby><cites>FETCH-LOGICAL-c478t-e5d630697a936c00623a5b00cefb3a3339cae0d71cb0230aa0075dfeb1b053df3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31029770$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holst, Jens Juul</creatorcontrib><title>The incretin system in healthy humans: The role of GIP and GLP-1</title><title>Metabolism, clinical and experimental</title><addtitle>Metabolism</addtitle><description>The incretin effect, the amplification of insulin secretion occurring when glucose is taken in orally as compared to infused intravenously, is one of the factors that help the body to tolerate carbohydrate/glucose ingestion. These include 1) amount and type of carbohydrates; 2) gastric emptying rate; 3) digestion and absorption of the carbohydrates; 4) secretion and effect of the incretin hormones; 5) disposition of absorbed nutrients/glucose. The incretin effect can also be viewed as the fraction of the ingested glucose load handled via gastrointestinal mechanisms (including the incretin effect); it is calculated by comparison of the amount of glucose required to copy, by intravenous infusion, the oral load. Typically, for 75 g of oral glucose, about 25 g are required. This means that the GastroIntestinal Glucose Disposal (GIGD) is 66%. Both the GIGD and the incretin effect depend on the amount of glucose ingested: for higher doses the GIGD may amount to 80%, which shows that this effect is a major contributor to glucose tolerance. The main mechanism behind it is stimulation of insulin secretion by a proportional secretion of the insulinotropic hormones GIP and GLP-1. Recently it has become possible to estimate their contributions in healthy humans using specific and potent receptor antagonists. Both hormones act to improve glucose tolerance (i.e. the antagonists impair tolerance) and their effects are additive. GIP seems to be quantitatively the most important, particularly regarding insulin secretion, whereas the action of GLP-1 is mainly displayed via inhibition of glucagon secretion. •The incretin effect refers to the amplification of insulin secretion after oral versus intravenous glucose•It is responsible for the disposal of most of ingested glucose and therefore essential for glucose tolerance•The incretin effect is mainly due to the actions of the gut hormones GIP and GLP-1•Antagonist studies revealed that GIP is most important for insulin secretion, GLP-1 for inhibition of glucagon secretion</description><subject>Cytokines - physiology</subject><subject>Glucagon-Like Peptide 1 - physiology</subject><subject>Health Status</subject><subject>Humans</subject><subject>Incretins - physiology</subject><subject>Insulin - metabolism</subject><subject>Signal Transduction - physiology</subject><issn>0026-0495</issn><issn>1532-8600</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOwzAQRS0EoqXwCSAv2SSM7dhu2ACqoFSqRBdlbTnORE2VR7ETpP49qVrYshqNdO48DiG3DGIGTD1s4xo7m7VVzIGlMSQxsOSMjJkUPJoqgHMyBuAqgiSVI3IVwhYAtJ6qSzISDHiqNYzJ83qDtGycx65saNiHDuuhpxu0VbfZ001f2yY80gPm2wppW9D5YkVtk9P5chWxa3JR2CrgzalOyOfb63r2Hi0_5ovZyzJyiZ52EcpcCVCptqlQDkBxYWUG4LDIhBVCpM4i5Jq5DLgAa4dbZV5gxjKQIi_EhNwf5-58-9Vj6ExdBodVZRts-2A4Z0pryRM5oPKIOt-G4LEwO1_W1u8NA3OQZ7bmJM8c5BlIzCBvyN2dVvRZjflf6tfWADwdARwe_S7Rm-BKbBzmpUfXmbwt_1nxA-QpgIw</recordid><startdate>201907</startdate><enddate>201907</enddate><creator>Holst, Jens Juul</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201907</creationdate><title>The incretin system in healthy humans: The role of GIP and GLP-1</title><author>Holst, Jens Juul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-e5d630697a936c00623a5b00cefb3a3339cae0d71cb0230aa0075dfeb1b053df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cytokines - physiology</topic><topic>Glucagon-Like Peptide 1 - physiology</topic><topic>Health Status</topic><topic>Humans</topic><topic>Incretins - physiology</topic><topic>Insulin - metabolism</topic><topic>Signal Transduction - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holst, Jens Juul</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Metabolism, clinical and experimental</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holst, Jens Juul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The incretin system in healthy humans: The role of GIP and GLP-1</atitle><jtitle>Metabolism, clinical and experimental</jtitle><addtitle>Metabolism</addtitle><date>2019-07</date><risdate>2019</risdate><volume>96</volume><spage>46</spage><epage>55</epage><pages>46-55</pages><issn>0026-0495</issn><eissn>1532-8600</eissn><abstract>The incretin effect, the amplification of insulin secretion occurring when glucose is taken in orally as compared to infused intravenously, is one of the factors that help the body to tolerate carbohydrate/glucose ingestion. These include 1) amount and type of carbohydrates; 2) gastric emptying rate; 3) digestion and absorption of the carbohydrates; 4) secretion and effect of the incretin hormones; 5) disposition of absorbed nutrients/glucose. The incretin effect can also be viewed as the fraction of the ingested glucose load handled via gastrointestinal mechanisms (including the incretin effect); it is calculated by comparison of the amount of glucose required to copy, by intravenous infusion, the oral load. Typically, for 75 g of oral glucose, about 25 g are required. This means that the GastroIntestinal Glucose Disposal (GIGD) is 66%. Both the GIGD and the incretin effect depend on the amount of glucose ingested: for higher doses the GIGD may amount to 80%, which shows that this effect is a major contributor to glucose tolerance. The main mechanism behind it is stimulation of insulin secretion by a proportional secretion of the insulinotropic hormones GIP and GLP-1. Recently it has become possible to estimate their contributions in healthy humans using specific and potent receptor antagonists. Both hormones act to improve glucose tolerance (i.e. the antagonists impair tolerance) and their effects are additive. GIP seems to be quantitatively the most important, particularly regarding insulin secretion, whereas the action of GLP-1 is mainly displayed via inhibition of glucagon secretion. •The incretin effect refers to the amplification of insulin secretion after oral versus intravenous glucose•It is responsible for the disposal of most of ingested glucose and therefore essential for glucose tolerance•The incretin effect is mainly due to the actions of the gut hormones GIP and GLP-1•Antagonist studies revealed that GIP is most important for insulin secretion, GLP-1 for inhibition of glucagon secretion</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31029770</pmid><doi>10.1016/j.metabol.2019.04.014</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0026-0495
ispartof Metabolism, clinical and experimental, 2019-07, Vol.96, p.46-55
issn 0026-0495
1532-8600
language eng
recordid cdi_proquest_miscellaneous_2216775245
source ScienceDirect Freedom Collection
subjects Cytokines - physiology
Glucagon-Like Peptide 1 - physiology
Health Status
Humans
Incretins - physiology
Insulin - metabolism
Signal Transduction - physiology
title The incretin system in healthy humans: The role of GIP and GLP-1
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A20%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20incretin%20system%20in%20healthy%20humans:%20The%20role%20of%20GIP%20and%20GLP-1&rft.jtitle=Metabolism,%20clinical%20and%20experimental&rft.au=Holst,%20Jens%20Juul&rft.date=2019-07&rft.volume=96&rft.spage=46&rft.epage=55&rft.pages=46-55&rft.issn=0026-0495&rft.eissn=1532-8600&rft_id=info:doi/10.1016/j.metabol.2019.04.014&rft_dat=%3Cproquest_cross%3E2216775245%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-e5d630697a936c00623a5b00cefb3a3339cae0d71cb0230aa0075dfeb1b053df3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2216775245&rft_id=info:pmid/31029770&rfr_iscdi=true